Core Insights - Maravai LifeSciences reported a first quarter revenue of $46.9 million, a 27.0% decrease compared to the same period in 2024, primarily due to a decline in nucleic acid production revenue [3][4][8] - The company experienced a net loss of $(52.9) million for the first quarter of 2025, which included a goodwill impairment of $12.4 million [4][11] - Maravai's revenue guidance for the full year 2025 remains unchanged, projected between $185.0 million and $205.0 million [6][7] Financial Performance - Nucleic Acid Production revenue was $28.8 million, reflecting a 37.5% year-over-year decrease, attributed to lower demand for research products and lack of high-volume CleanCap orders [3][8] - Biologics Safety Testing revenue was relatively flat at $18.1 million, showing a slight decrease of 0.3% year-over-year [3][8] - Adjusted EBITDA for the first quarter was $(10.5) million, a significant decline from $7.8 million in the same quarter of 2024 [4][12] Management Commentary - CEO Trey Martin emphasized the company's commitment to a return-to-growth strategy despite a challenging macroeconomic environment, highlighting customer focus and differentiated technologies as key strengths [2][4] - The management plans to navigate the evolving landscape to drive long-term value for the company [2][4] Revenue Guidance - The revenue guidance for 2025 does not include potential revenue from high-volume CleanCap orders or new acquisitions [5][6] - The guidance reflects expectations based on the existing base business and is subject to various risks and uncertainties [5][6] Operational Insights - The total operating expenses for the first quarter were $96.0 million, up from $83.0 million in the prior year, driven by increased costs in various segments [11][12] - The company reported a loss from operations of $(49.2) million for the first quarter, compared to $(18.9) million in the same period last year [11][12]

Core Viewpoint - A class action securities lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for alleged securities fraud affecting investors between August 7, 2024, and February 24, 2025 [1][2]. Group 1: Allegations and Company Issues - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2]. - It is alleged that the Company inaccurately recognized revenue on certain transactions during fiscal 2024 [2]. - The complaint also states that Maravai's goodwill was overstated, leading to materially misleading positive statements about the Company's business and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until May 5, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Maravai LifeSciences Holdings, Inc. reported disappointing fourth-quarter 2024 earnings, missing analyst expectations and facing a significant price target downgrade due to concerns over its financial outlook and ongoing legal issues [1][4]. Financial Performance - The company posted an adjusted loss per share of $0.06, which was wider than the expected loss of $0.04, with quarterly revenue at $56.6 million, slightly below the consensus forecast of $56.67 million [2]. - For the full year, Maravai reported revenue of $259 million, consistent with its guidance, but its GAAP net loss widened to $260 million from a $138 million loss in 2023 [3]. Analyst Reactions - Following the disappointing results, Stifel analysts reduced their price target for Maravai by 50%, from $10.00 to $5.00, reflecting concerns about the company's near-term financial outlook and weaker-than-expected revenues and EBITDA [4]. Legal Issues - Maravai is facing a securities class action lawsuit alleging improper accounting practices, including failure to disclose significant financial issues and misleading statements [5]. - The lawsuit claims that Maravai's stock price fell nearly 22% after the company announced a delay in its fiscal 2024 earnings release due to the need for more time to complete its financial close [5]. Accounting Concerns - CFO Kevin Herde acknowledged errors in revenue recognition, specifically a $3.9 million misrecording due to timing issues related to a shipment [6]. - The company also recorded an $11.9 million non-cash goodwill impairment charge related to its Alphazyme acquisition, indicating material weaknesses in internal controls over revenue recognition and goodwill assessments [7][9].

Core Viewpoint - A class action securities lawsuit has been filed against Maravai LifeSciences Holdings, Inc. alleging securities fraud that affected investors between August 7, 2024, and February 24, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Maravai LifeSciences lacked adequate internal controls over financial reporting related to revenue recognition [2]. - It is alleged that the Company inaccurately recognized revenue on certain transactions during fiscal 2024 [2]. - The complaint also states that the goodwill of the Company was overstated, leading to materially misleading positive statements about its business and operations [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until May 5, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for alleged securities fraud affecting investors between August 7, 2024, and February 24, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Maravai LifeSciences lacked adequate internal controls over financial reporting related to revenue recognition [2]. - It is alleged that the company inaccurately recognized revenue on certain transactions during fiscal 2024 [2]. - The complaint also states that Maravai's goodwill was overstated, leading to materially misleading positive statements about the company's business and prospects [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until May 5, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI). Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=1461 ...

Company Overview - Maravai LifeSciences, Inc. is a global provider of life science reagents and services, supporting researchers and biotech innovators [3] - The company specializes in products for drug therapies, diagnostics, and novel vaccines, and supports research on human diseases [3] - Maravai's offerings include nucleic acid synthesis and biologics safety testing, serving leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies [3] Upcoming Financial Announcement - Maravai plans to announce its first quarter 2025 financial and operating results after market close on May 12, 2025 [1] - A conference call and webcast will be held on the same day at 2:00 p.m. PT / 5:00 p.m. ET [1] Conference Call Participation - Participants can join the conference call by dialing (800) 343-4849 or (203) 518-9848, referencing Conference ID MARAVAI [2] - The call will also be available via live or archived webcast on the Maravai website [2]

NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) --   WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) between August 7, 2024 and February 24, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2025 lead plaintiff deadline. SO WHAT: If you purchased Maravai securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency f ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team: http ...

NEW YORK, April 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zl ...